Thesis icon

Thesis

Drug-device development: cancer immunotherapy with therapeutic, ultrasound-mediated delivery

Abstract:

Tumour and tumour microenvironment exploitation of immunologic checkpoints like PD-L1 can enable immune evasion. Recent advances in oncology, have brought forward antibody drugs, such as anti-PD-L1, capable of blocking and/or mediating the eradication of cells that express PD-L1. Despite promise across a wide range of indications, clinically such agents meaningfully extend survival only in a fraction of patients treated.

Immature, heterogenous blood vessels, elevated interstitial p...

Expand abstract

Actions


Authors


More by this author
Division:
MSD
Department:
Biomedical Services
Role:
Depositor, Author

Contributors

Role:
Supervisor
Role:
Supervisor
ORCID:
0000-0001-8792-7818
Role:
Supervisor
Role:
Supervisor
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
UUID:
uuid:5a7f7ed8-b4aa-4ede-960a-106f2aed0425

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP